Literature DB >> 12912931

Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy.

Matthew W Harding1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12912931

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  13 in total

1.  Systemic therapy for metastatic renal cell carcinoma: a review and update.

Authors:  Joshua E Logan; Edward N Rampersaud; Geoffrey A Sonn; Karim Chamie; Arie S Belldegrun; Allan J Pantuck; Dennis J Slamon; Fairooz F Kabbinavar
Journal:  Rev Urol       Date:  2012

2.  Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.

Authors:  Eric J Sherman; Lara A Dunn; Alan L Ho; Shrujal S Baxi; Ronald A Ghossein; Matthew G Fury; Sofia Haque; Cami S Sima; Grace Cullen; James A Fagin; David G Pfister
Journal:  Cancer       Date:  2017-06-29       Impact factor: 6.860

Review 3.  The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells.

Authors:  M R Moniri; L-J Dai; G L Warnock
Journal:  Cancer Gene Ther       Date:  2014-01-03       Impact factor: 5.987

4.  Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases.

Authors:  Masashi Takano; Yoshihiro Kikuchi; Kazuya Kudoh; Tomoko Goto; Kenichi Furuya; Ryoko Kikuchi; Tsunekazu Kita; Keiichi Fujiwara; Tanri Shiozawa; Daisuke Aoki
Journal:  Int J Clin Oncol       Date:  2011-01-18       Impact factor: 3.402

Review 5.  FKBP51 and the molecular chaperoning of metabolism.

Authors:  Kathryn B Smedlund; Edwin R Sanchez; Terry D Hinds
Journal:  Trends Endocrinol Metab       Date:  2021-09-01       Impact factor: 12.015

6.  Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib.

Authors:  Chris Coppin
Journal:  Biologics       Date:  2010-05-25

7.  Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets.

Authors:  Charles Swanton; James M Larkin; Marco Gerlinger; Aron C Eklund; Michael Howell; Gordon Stamp; Julian Downward; Martin Gore; P Andrew Futreal; Bernard Escudier; Fabrice Andre; Laurence Albiges; Benoit Beuselinck; Stephane Oudard; Jens Hoffmann; Balázs Gyorffy; Chris J Torrance; Karen A Boehme; Hansjuergen Volkmer; Luisella Toschi; Barbara Nicke; Marlene Beck; Zoltan Szallasi
Journal:  Genome Med       Date:  2010-08-11       Impact factor: 11.117

8.  Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.

Authors:  Janice P Dutcher; Paul de Souza; David McDermott; Robert A Figlin; Anna Berkenblit; Alexandra Thiele; Mizue Krygowski; Andrew Strahs; Jay Feingold; Gary Hudes
Journal:  Med Oncol       Date:  2009-02-20       Impact factor: 3.064

9.  Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity.

Authors:  Rosalie Fisher; James Larkin; Charles Swanton
Journal:  EPMA J       Date:  2011-12-22       Impact factor: 6.543

Review 10.  Targeted therapy for advanced renal cell carcinoma.

Authors:  C Coppin; L Le; F Porzsolt; T Wilt
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.